相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
Emad A. Rakha et al.
CLINICAL CANCER RESEARCH (2009)
Peroxisome proliferator-activated receptor-alpha (PPARA) genetic polymorphisms and breast cancer risk:: a Long Island ancillary study
Amanda K. Golembesky et al.
CARCINOGENESIS (2008)
Basal-like breast cancer: A critical review
Emad A. Rakha et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Molecular testing for somatic mutations in common cancers: the views of UK oncologists
S. Wordsworth et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/triple-negative'' breast cancer cell lines growing in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999
R. W. Blamey et al.
EUROPEAN JOURNAL OF CANCER (2007)
Peroxisomal proliferator-activated receptor-α-dependent inhibition of endothelial cell proliferation and tumorigenesis
Ambra Pozzi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection
Fei Huang et al.
CANCER RESEARCH (2007)
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer
Suet F. Chin et al.
GENOME BIOLOGY (2007)
Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression
E. A. Rakha et al.
HISTOPATHOLOGY (2007)
Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance
Emad A. Rakha et al.
EUROPEAN JOURNAL OF CANCER (2006)
PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome
Catherine Fievet et al.
CURRENT OPINION IN PHARMACOLOGY (2006)
Epidermal growth factor receptor targeting in cancer
John Mendelsohn et al.
SEMINARS IN ONCOLOGY (2006)
Crystal structure of human guanosine monophosphate reductase 2 (GMPR2) in complex with GMP
JX Li et al.
JOURNAL OF MOLECULAR BIOLOGY (2006)
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
CA Livasy et al.
MODERN PATHOLOGY (2006)
High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses
DM Abd El-Rehim et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype
SR Lakhani et al.
CLINICAL CANCER RESEARCH (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Peroxisome proliferator-activated receptor α gene variation influences age of onset and progression of type 2 diabetes
DM Flavell et al.
DIABETES (2005)
The prognostic implication of the basal-like (cyclin Ehigh/p27low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer
WD Foulkes et al.
CANCER RESEARCH (2004)
Peroxisome proliferator-activated receptor (PPAR)-α:: A pharmacological target with a promising future
DH van Raalte et al.
PHARMACEUTICAL RESEARCH (2004)
Different proliferative activity of the glandular and myoepithelial lineages in benign proliferative and early malignant breast diseases
A Bánkfalvi et al.
MODERN PATHOLOGY (2004)
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
TO Nielsen et al.
CLINICAL CANCER RESEARCH (2004)
Loss of CD59 expression in breast tumours correlates with poor survival
Z Madjd et al.
JOURNAL OF PATHOLOGY (2003)
C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer
CM Schlotter et al.
BREAST CANCER RESEARCH (2003)
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome
M van de Rijn et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Peroxisome proliferator-activated receptor α in the human breast cancer cell lines MCF-7 and MDA-MB-231
KM Suchanek et al.
MOLECULAR CARCINOGENESIS (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Towards a novel classification of human malignancies based on gene expression patterns
AA Alizadeh et al.
JOURNAL OF PATHOLOGY (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)